Tag: ECYT

Blue Horseshoe Stocks: Options Ideas & More

SPDR S&P 500 ETF (SPY)

As you are probably aware the SPY (the markets as a whole) had been on a historic run starting in early 2016 which persisted through January of this year, when we experienced some of the biggest selloffs in market history. The SPY began to rebound earlier this month, and was making a pretty good run at a recovery until yesterday brought another significant backslide.

Despite yesterday’s hiccup, the SPY has been in a general uptrend for the last couple of weeks, and today, it looks like we could resume the path toward ascension. We’ll be ;looking for the markets to go green today, which could produce some notable opportunities in the SPY 02/28 $275-276 Calls*.

*Please note that these contracts expire today, thus the associated risk is that of trading weekly options on a Friday. It should never be attempted unless you are an expert level trader with disposable funds.

The TJX Companies, inc. TJX

TJX is exhibiting a considerable surge in premarket trading today. Despite missing EPS estimates in their Q4 earnings call, the stock is gapping up to the tune of 8% this morning.

When we see a monster gapper like this, we generally look to signal a range of options calls that will come into play in a dip-and-rip scenario, which are quite common in instances such as these. We will be tracking the TJX 03/16 $80-85 Calls.

Extended Watchlist:
ECYT, ENPH, CTRV, GLNG, NIHD, VEEV

Blue Horseshoe Stocks: KOOL, TIF Recaps & More

Endocyte, Inc. ECYT

We initially took notice of ECYT on Monday morning just as the company announced it had completed a worldwide license for its prostate cancer treatment now moving into Phase-3 development.

The stock made a solid 130% rip from 1.63 to 3.75 that morning, but it was only just getting started. Yesterday morning the stock ran hard once again, reaching its peak at a new annual high of 6.55. That puts the total on our two-day observed increased of 302% while volume over the same period has been literally hundreds of times greater than the monthly average prior to Monday’s bombshell PR.

Tiffany & Co. TIF – Options Update

As we were just mentioning yesterday morning, we’ve been tracking the TIF 10/20 $92-93 Calls since the morning of September 28th. TIF stock has maintained its gradual ascent since that time, and with that, we’ve seen the potential gains made off of our ideas grow along with it.

The following ranges represent the lows from the 28th to the highs achieved during yesterday’s session:

$92 Calls – Range: 1.00-2.20 – Max Gain: 120%
$92.50 Calls – Range: .85-2.19  – Max Gain: 158%.
$93 Calls – Range: .83-2.15 – Max Gain: 159%

Cesca Therapeutics Inc. KOOL

After including KOOL in yesterday morning’s watchlist, we watched as the stock made a very nice intraday run on the chart with the help of some positive news.

The U.S. Patent and Trademark Office issued a Notice of Allowance on the company’s patent application for its proprietary method for separating target cells from blood, marrow, and other sources.

That prompted a solid boost from 3.96 to 6.44 on the day, marking an intraday push of 63% which was accompanied by the trading of 223X more shares than the monthly average!

Extended Watchlist:
CATB, RGSE, CAPR, ATNM, VKTX, MNKD, BIOP,  HTBX

Blue Horseshoe Stocks: ECYT Recap & More

Endocyte, Inc. ECYT

We took notice of ECYT yesterday morning during our routine premarket scan, and due to some abnormal activity, we decided to include it in the daily watchlist.

It turned out to be a splendid idea, with the stock ultimately recording a hugely bullish session. ECYT traded from its low of 1.63 just following the open, to its high of 3.75 just prior to the close. It worked out to a single-session rip of 130% and it came on over 180X the monthly average volume. The stock has also hit a new high of 6.07 in the premarket this morning, pushing our observed move in less than 24 hours to a whopping 272%

It was especially impressive because of the timing, which couldn’t have been any better. Prior to yesterday’s session the stock was stagnating for several months. The move was catalyzed primarily by the announcement of the completion of a worldwide license on the company’s prostate cancer treatment, which will be moving on to Phase III development. (>>View PR)

Rigel Pharmaceuticals, Inc. RIGL

Speaking of solidly-timed calls on pharma plays, we also caught RIGL and included it in yesterday’s premarket report. It didn’t see the type of move that the previously mentioned stock, but got off to a respectable start.

RIGL traded in a range from 2.85-3.42, a modest rise of 20%, but did so on nearly 17X the monthly average volume, and closed near its high of day. We’ll continue to observe this play to see if it can establish a sustained uptrend.

Capricor Therapeutics, Inc. CAPR

We were just updating our readers yesterday morning on the moves CAPR had made since we had alerted it onSeptember 20th from its low of 1.80.

What followed was another nice session for the stock, which ran to a new high of 4.25; a total increase of 136% in a span of just eight trading days.


Tiffany & Co. TIF – Options Update

We also want to quickly update readers on our TIF options ideas that we submitted on the morning of September 28th, the TIF 10/20 $92-93 Calls. The stock has been in a continuous bullish pattern since then, and those calls made some pretty nice gains in the process.

$92 Calls – Range: 1.00-2.13 – Max Gain: 113%
$92.50 Calls – Range: .85-1.74  – Max Gain: 105%.
$93 Calls – Range: .83-1.88 – Max Gain: 127%

Extended Watchlist:
ETRM, VICL, DMPI, TA, KOOL, CATB